arrow
R

Robert J. Kreitman

national institutes of health
H指数:70
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL variant

毛细胞白血病(HCL)和HCL变异型的诊断与管理更新共识指南

Blood
IF23.1
2026-04-160
PRE
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells

针对IGHV4-34 b细胞受体的嵌合抗原受体T细胞特异性消除肿瘤性和自身免疫性b细胞

2026-02-040
PRE
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia

免疫球蛋白同种型内多样化测量的结果细化了慢性淋巴细胞白血病中IGHV突变状态的临床影响。

Leukemia
IF13.4
2025-06-180
OAAI
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms
LEUKEMIA
IF13.4
2024-06-084
OAAI
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
2023-04-140
PRE
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
2023-04-1495
OAAI
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
2022-12-229
OAAI
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
2022-12-1313
OAAI
Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries

OAS1无意义介导的衰变的遗传调控与欧洲和非洲祖先患者的新型冠状病毒肺炎住院有关

2022-07-1466
OAAI
Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

克拉屈滨与利妥昔单抗并发毛细胞白血病变体的II期研究的长期随访

2021-11-2420
OAAI
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

毛细胞白血病与治疗指南的新型冠状病毒肺炎适应

LEUKEMIA
IF13.4
2021-05-0429
OAAI
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
2021-02-2458
OAAI